Edgeworthia papyrifera Regulates Osteoblast and Osteoclast Differentiation In Vitro and Exhibits Anti-osteoporosis Activity in Animal Models of Osteoporosis

Abstract

Osteoporosis is a clinical condition characterized by low bone strength that leads to an increased risk of fracture. Strategies for the treatment of osteoporosis involve inhibition of bone resorption by osteoclasts and an increase of bone formation by osteoblasts. Here, we identified the extract derived from the stem part of Edgeworthia papyrifera that enhanced differentiation of MC3T3-E1 cells to osteoblast-like cells and inhibited osteoclast differentiation of RAW 264.7 cells in vitro. In support of our observation, rutin and daphnoretin, which were previously reported to inhibit osteoclast differentiation, were identified in E. papyrifera extract. In an animal model of osteoporosis, the ovariectomy-induced increases in bone resorption biomarkers such as pyridinoline and tartrate-resistant acid phosphatase were significantly reduced by E. papyrifera extract administration at 25.6 and 48.1%, respectively. Furthermore, the ovariectomy-induced bone loss in animal models of osteoporosis was significantly prevented by the administration of E. papyrifera in our study. Taking these observations into account, we suggest that E. papyrifera is an interesting candidate for further exploration as an anti-osteoporotic agent.

Key words

Edgeworthia papyrifera - Thymelaeaceae - osteoblast - osteoclast - osteoporosis - ovariectomy

• References

• 1 Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006; 1092: 385-396
• 2 Chambers TJ, Fuller K. How are osteoclasts induced to resorb bone?. Ann N Y Acad Sci 2011; 1240: 1-6
• 3 Spreafico A, Frediani B, Capperucci C, Chellini F, Paffetti A, DʼAmbrosio C, Bernardini G, Mini R, Collodel G, Scaloni A, Marcolongo R, Santucci A. A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics 2006; 6: 3520-3532
• 4 Bernardini G, Braconi D, Spreafico A, Santucci A. Post-genomics of bone metabolic dysfunctions and neoplasias. Proteomics 2012; 12: 708-721
• 5 Boskey AL, Imbert L. Bone quality changes associated with aging and disease: a review. Ann N Y Acad Sci 2017; 1410: 93-106
• 6 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795
• 7 Ng KW, Martin TJ. New therapeutics for osteoporosis. Curr Opin Pharmacol 2014; 16: 58-63
• 8 Appelman-Dijkstra NM, Papapoulos SE. Novel approaches to the treatment of osteoporosis. Best Pract Res Clin Endocrinol Metab 2014; 28: 843-857
• 9 Pazianas M, Kim SM, Yuen T, Sun L, Epstein S, Zaidi M. Questioning the association between bisphosphonates and atypical femoral fractures. Ann N Y Acad Sci 2015; 1335: 1-9
• 10 Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
• 11 Diab DL, Watts NB. Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes 2013; 20: 501-509
• 12 Khajuria DK, Razdan R, Mahapatra DR. Drugs for the management of osteoporosis: a review. Rev Bras Reumatol 2011; 51: 365-371 379–382
• 13 Baek JM, Kim JY, Cheon YH, Park SH, Ahn SJ, Yoon KH, Oh J, Lee MS. Dual effect of Chrysanthemum indicum extract to stimulate osteoblast differentiation and inhibit osteoclast formation and resorption In Vitro . Evid Based Complement Alternat Med 2014; 2014: 176049
• 14 Visagie A, Kasonga A, Deepak V, Moosa S, Marais S, Kruger MC, Coetzee M. Commercial Honeybush (Cyclopia spp.) tea extract inhibits osteoclast formation and bone resorption in RAW264.7 murine macrophages – an in vitro study. Int J Environ Res Public Health 2015; 12: 13779-13793
• 15 Zhang Y, Guan H, Li J, Fang Z, Chen W, Li F. Amlexanox suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss. Sci Rep 2015; 5: 13575
• 16 Yogesh HS, Chandrashekhar VM, Katti HR, Ganapaty S, Raghavendra HL, Gowda GK, Goplakhrishna B. Anti-osteoporotic activity of aqueous-methanol extract of Berberis aristata in ovariectomized rats. J Ethnopharmacol 2011; 134: 334-338
• 17 Nikolic D, Godecke T, Chen SN, White J, Lankin DC, Pauli GF, van Breemen RB. Mass spectrometric dereplication of nitrogen-containing constituents of black cohosh (Cimicifuga racemosa L.). Fitoterapia 2012; 83: 441-460
• 18 Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 1999; 14: 893-903
• 19 Zhang Z, Jimi E, Bothwell AL. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. J Immunol 2003; 171: 3620-3626
• 20 Hu XJ, Jin HZ, Xu WZ, Chen M, Liu XH, Zhang W, Su J, Zhang C, Zhang WD. Anti-inflammatory and analgesic activities of Edgeworthia chrysantha and its effective chemical constituents. Biol Pharm Bull 2008; 31: 1761-1765
• 21 Li XN, Tong SQ, Cheng DP, Li QY, Yan JZ. Coumarins from Edgeworthia chrysantha . Molecules 2014; 19: 2042-2048
• 22 Brandi ML. Microarchitecture, the key to bone quality. Rheumatology (Oxford) 2009; 48 (Suppl. 04) iv3-8
• 23 Lee YM, Kim IS, Lim BO. Black rice (Oryza sativa L.) fermented with Lactobacillus casei attenuates osteoclastogenesis and ovariectomy-induced osteoporosis. Biomed Res Int 2019; 2019: 5073085
• 24 Juttner KV, Perry MJ. High-dose estrogen-induced osteogenesis is decreased in aged RUNX2(±) mice. Bone 2007; 41: 25-32
• 25 Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013; 382: 50-56
• 26 Li JY, Tawfeek H, Bedi B, Yang X, Adams J, Gao KY, Zayzafoon M, Weitzmann MN, Pacifici R. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci U S A 2011; 108: 768-773
• 27 Liu S, Madiai F, Hackshaw KV, Allen CE, Carl J, Huschart E, Karanfilov C, Litsky A, Hickey CJ, Marcucci G, Huja S, Agarwal S, Yu J, Caligiuri MA, Wu LC. The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis. PLoS One 2011; 6: e17161
• 28 Carey HA, Bronisz A, Cabrera J, Hildreth 3rd BE, Cuitino M, Fu Q, Ahmad A, Toribio RE, Ostrowski MC, Sharma SM. Failure to target RANKL signaling through p38-MAPK results in defective osteoclastogenesis in the Microphthalmia cloudy-eyed mutant. J Cell Physiol 2016; 231: 630-640
• 29 Mediero A, Perez-Aso M, Cronstein BN. Activation of EPAC1/2 is essential for osteoclast formation by modulating NFkappaB nuclear translocation and actin cytoskeleton rearrangements. FASEB J 2014; 28: 4901-4913
• 30 Kyung TW, Lee JE, Shin HH, Choi HS. Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF-alpha by inhibiting activation of NF-kappaB. Exp Mol Med 2008; 40: 52-58
• 31 Junfei H, Tingting F, Yi L, Xue Z, Lizhen C, Ying Z. Research on active daphnoretin on inhibiting osteoclast differentiation and promoting osteoclast proliferation in vitro . Pharmacology and Clinics of Chinese Materia Medica 2016; 32: 69-72